Qureator

Qureator is a biomedical company founded in 2017 and headquartered in San Diego, California. The company's Microphysiological Systems (MPS), known as Curiochips, aim to recapitulate the complexity of tissue microenvironments, providing microscale 3D cell culture conditions. Qureator's focus is on developing novel platforms and high-throughput disease models for precision medicine in areas of high unmet medical needs. The company's MPS enable investigators to perform co-cultures of multiple cell types in 3D and high-throughput screenings for biomedical research and drug discovery. Offering a variety of patient-derived in vitro models in organs-on-chips, Qureator's technology closely recapitulates the pathophysiology of diseases such as fibrosis, oncology, angiogenesis, ocular disease, and vasculogenesis. The company has garnered significant attention through collaborations with pharmaceutical companies and academic institutions for assay development, safety evaluation, and drug discovery. The conventional preclinical testing challenges have led to increased costs and time in drug discovery and development. In response, the company, along with the industry, has worked towards solving the mismatched preclinical testing for human drug treatments by developing several in vitro testing platforms. Qureator's Series A investment of $9.00M on March 17, 2022, signifies investor confidence in the potential of their Organ-on-a-Chip technology to mimic human model systems and evaluate drug candidates.